We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Viral vector-based therapeutic HPV vaccines.
- Authors
Ji, Teng; Liu, Yuchuan; Li, Yutong; Li, Chuanfen; Han, Yingyan
- Abstract
Replication-defective viral vector vaccines have several advantages over conventional subunit vaccines, including potent antibody responses, cellular responses critical for eliminating pathogen-infected cells, and the induction of highly immunogenic and durable immune responses without adjuvants. The Human papillomavirus (HPV), a microorganism with over 200 genotypes, plays a crucial role in inducing human tumors, with the majority of HPV-related malignancies expressing HPV proteins. Tumors associated with HPV infection, most of which result from HPV16 infection, include those affecting the cervix, anus, vagina, penis, vulva, and oropharynx. In recent years, the development of therapeutic HPV vaccines utilizing viral vectors for the treatment of premalignant lesions or tumors caused by HPV infection has experienced rapid growth, with numerous research pipelines currently underway. Simultaneously, screening for optimal antigens requires more basic research and more optimized methods. In terms of preclinical research, we present the various models used to assess vaccine efficacy, highlighting their respective advantages and disadvantages. Further, we present current research status of therapeutic vaccines using HPV viral vectors, especially the indications, initial efficacy, combination drugs, etc. In general, this paper summarizes current viral vector therapeutic HPV vaccines in terms of HPV infection, antigen selection, vectors, efficacy evaluation, and progress in clinical trials.
- Subjects
GENETIC vectors; HUMAN papillomavirus vaccines; HUMAN papillomavirus; VIRAL vaccines; VACCINE effectiveness; GENITAL warts
- Publication
Clinical & Experimental Medicine, 2024, Vol 24, Issue 1, p1
- ISSN
1591-8890
- Publication type
Article
- DOI
10.1007/s10238-024-01470-5